ClearPoint Neuro to Announce Second Quarter 2021 Results August 10, 2021

Rhea-AI Summary

ClearPoint Neuro, Inc. (Nasdaq: CLPT) will announce its 2021 second-quarter financial results on August 10, 2021, after market close. A live broadcast will take place on the same day at 4:30 p.m. Eastern time. Those unable to attend can access a replay until September 10, 2021. The Company focuses on enabling therapies for neurological disorders via its ClearPoint Neuro Navigation System, which has FDA clearance and is deployed in over 60 active sites globally. The Company has partnered with over 30 pharmaceutical firms and has conducted more than 4,500 cases to date.

Positive

• ClearPoint Neuro Navigation System has FDA clearance and CE-mark.
• Installed in over 60 active sites in the U.S., Canada, and Europe.
• Partnerships with over 30 pharmaceutical and academic institutions.
• Over 4,500 procedures performed with the Company's technology.

Negative

• Future revenue uncertainties from ClearPoint products.
• Risks associated with the impact of COVID-19 on operations.

SOLANA BEACH, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021, after the market close.

Investors and analysts are invited to listen to a live broadcast review of the Company's 2021 second quarter on Tuesday, August 10, 2021 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here by entering meeting number: 13721705. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until September 10, 2021, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at www.clearpointneuro.com, on the “Investor Relations” page.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint^® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with over 30 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.  

Forward-Looking Statements

Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2021, which the Company intends to file with the Securities and Exchange Commission on or before August 16, 2021.

FAQ

When will ClearPoint Neuro release its Q2 2021 financial results?

ClearPoint Neuro will release its Q2 2021 financial results on August 10, 2021, after market close.

What time is the ClearPoint Neuro Q2 2021 results conference call?

The conference call for ClearPoint Neuro's Q2 2021 results is scheduled for August 10, 2021, at 4:30 p.m. Eastern time.

How can I listen to the ClearPoint Neuro Q2 2021 earnings call?

Investors can listen to the live broadcast online or by calling (877) 407-9034 within the U.S. and (201) 493-6737 for international calls.

What products does ClearPoint Neuro offer?

ClearPoint Neuro offers solutions for deep brain stimulation, laser ablation, biopsy, and drug delivery to the brain.

What are the key risks highlighted by ClearPoint Neuro?

Key risks include uncertainties regarding future revenues and the effects of COVID-19 on the business.